Loading clinical trials...

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | Clinical Trials | Clareo Health

COMPLETEDPHASE3

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas

NCT01777152•Seagen Inc.

View on ClinicalTrials.gov

Summary

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with newly diagnosed, CD30-positive mature T-cell lymphomas
•Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT
•Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

Exclusion Criteria

•History of another primary invasive malignancy that has not been in remission for at least 3 years
•Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas or mycosis fungoides
•History of progressive multifocal leukoencephalopathy (PML)
•Cerebral/meningeal disease related to the underlying malignancy

Locations (144)

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States

City of Hope National Medical Center

Duarte, California, United States

Stanford Cancer Center

Stanford, California, United States

Shands Cancer Center / University of Florida

Gainesville, Florida, United States

Orlando Health, Inc.

Orlando, Florida, United States

University of Illinois at Chicago

Chicago, Illinois, United States

Cardinal Bernardin Cancer Center / Loyola University Medical Center

Maywood, Illinois, United States

Holden Comprehensive Cancer Center / University of Iowa

Iowa City, Iowa, United States

University of Kansas Cancer Center

Westwood, Kansas, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Key Dates

Start Date

January 31, 2013

Primary Completion Date

August 15, 2018

Completion Date

October 2, 2020

Last Updated

November 30, 2021

Enrollment

452

ACTUAL participants

Conditions

Anaplastic Large-Cell LymphomaNon-Hodgkin LymphomaT-Cell Lymphoma

Interventions

brentuximab vedotin

DRUG

doxorubicin

DRUG

prednisone

DRUG

vincristine

DRUG

cyclophosphamide

DRUG

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

NCT07388563

Lymphoma, T Cell, PeripheralT-cell Lymphoma+4 more

View study

RECRUITINGPHASE1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 30, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Inclusion Criteria

Exclusion Criteria

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL